Trial · NCT00039130
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
NCT00039130, Phase 2, Completed, Alliance for Clinical Trials in Oncology; results first posted 2014-10-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia. Trials, record NCT00039130. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00039130
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
- NCT number
- NCT00039130
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 105 participants, actual
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
- First posted
- 2003-01-27
- Last updated
- 2023-08-21
- Results first posted
- 2014-10-22
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate | 6 months | Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease. |
| Secondary | 2 Year Event Free Survival | 2 years | Percentage of patients who were event free at 2 years. The 2-year event free rate was estimated using the Kaplan Meier method. An event is defined as death, progression or treatment failure. |
| Secondary | 2 Year Overall Survival | 2 years | Percentage of participants who were alive at 2 years. The 2 year survival, with 95% confidence interval, was estimated using the Kaplan Meier method. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Response Rate | 6 months | percentage of participants | NUMBER | |
| SECONDARY | 2 Year Event Free Survival | 2 years | percentage of participants | NUMBER | |
| SECONDARY | 2 Year Overall Survival | 2 years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Response Rate | Rituximab With High Intensity Chemotherapy | 83 | 95% Confidence Interval 74 to 90 | percentage of participants | |
| 2 Year Event Free Survival | Rituximab With High Intensity Chemotherapy | 78 | 95% Confidence Interval 69 to 85 | percentage of participants | |
| 2 Year Overall Survival | Rituximab With High Intensity Chemotherapy | 80 | 95% Confidence Interval 71 to 86 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rituximab With High Intensity Chemotherapy | 105 | |
| Overall Study | COMPLETED | Rituximab With High Intensity Chemotherapy | 75 | |
| Overall Study | NOT COMPLETED | Rituximab With High Intensity Chemotherapy | 30 |
Source ClinicalTrials.gov
Adverse events427
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood disorder | Blood and lymphatic system disorders | Rituximab With High Intensity Chemotherapy | 2 | 105 | 2 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Rituximab With High Intensity Chemotherapy | 65 | 105 | 130 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Rituximab With High Intensity Chemotherapy | 100 | 105 | 642 |
| other | Lymphatic disorder | Blood and lymphatic system disorders | Rituximab With High Intensity Chemotherapy | 1 | 105 | 1 |
| other | Transfusion: Platelets | Blood and lymphatic system disorders | Rituximab With High Intensity Chemotherapy | 18 | 105 | 41 |
| other | Transfusion: pRBCs | Blood and lymphatic system disorders | Rituximab With High Intensity Chemotherapy | 18 | 105 | 72 |
| other | Arrhythmia | Cardiac disorders | Rituximab With High Intensity Chemotherapy | 4 | 105 | 4 |
| other | Arrhythmia supraventricular | Cardiac disorders | Rituximab With High Intensity Chemotherapy | 4 | 105 | 5 |
| other | Atrial fibrillation | Cardiac disorders | Rituximab With High Intensity Chemotherapy | 2 | 105 | 2 |
| other | Cardiac disorder | Cardiac disorders | Rituximab With High Intensity Chemotherapy | 10 | 105 | 10 |
1 to 10 of 427Source ClinicalTrials.gov
See all 427 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rituximab With High Intensity Chemotherapy | ||
| Total, other adverse events | Rituximab With High Intensity Chemotherapy | 101 | 105 |
| Total, serious adverse events | Rituximab With High Intensity Chemotherapy | 61 | 105 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24428673 | RESULT |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA031946 | Cancer and Leukemia Group B | BERTAGNOLLI, MONICA M | BRIGHAM AND WOMEN'S HOSPITAL | NATIONAL CANCER INSTITUTE | 1985 to 2013 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00039130
GET https://conductscience.org/api/trials/v1/NCT00039130/events?page=2